The Pharmagellan Guide to Biotech Forecasting and Valuation

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to build and analyze forecasts and valuations of R&D-stage drugs. This book is for you. The Pharmagellan Guide to Biotech Forecasting and Valuation is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage assets and companies. - Vetted benchmarks for key drivers of income, expenses, and valuation. - Proprietary analyses by Pharmagellan's experienced consulting team. - Over 150 current references from peer-reviewed research, industry white papers, and SEC filings. Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.